Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Treasury Shares (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Treasury Shares for 8 consecutive years, with $3.4 million as the latest value for Q1 2026.

  • Quarterly Treasury Shares rose 11.5% to $3.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Feb 2026, up 11.5% year-over-year, with the annual reading at $2.2 million for FY2025, 14.82% up from the prior year.
  • Treasury Shares for Q1 2026 was $3.4 million at Nurix Therapeutics, up from $2.2 million in the prior quarter.
  • The five-year high for Treasury Shares was $3.4 million in Q1 2026, with the low at $1548.0 in Q1 2024.
  • Average Treasury Shares over 5 years is $1.7 million, with a median of $1.6 million recorded in 2023.
  • The sharpest move saw Treasury Shares crashed 99.9% in 2024, then surged 195381.91% in 2025.
  • Over 5 years, Treasury Shares stood at $784824.0 in 2022, then skyrocketed by 58.77% to $1.2 million in 2023, then soared by 56.98% to $2.0 million in 2024, then rose by 14.82% to $2.2 million in 2025, then soared by 50.23% to $3.4 million in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $3.4 million, $2.2 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.